2-((2-(三氟甲基)苄基)氧基)异吲哚啉e-1,3-二酮 | 321430-37-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-((2-(三氟甲基)苄基)氧基)异吲哚啉e-1,3-二酮
• 英文名称: 2-((2-(Trifluoromethyl)benzyl)oxy)isoindoline-1,3-dione
• 英文别名: 2-[[2-(trifluoromethyl)phenyl]methoxy]isoindole-1,3-dione
• CAS: 321430-37-9
• 化学式: C₁₆H₁₀F₃NO₃
• 分子量: 321.256
• InChiKey: MDJFOOWYLORBGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2925190090

反应信息

• 作为反应物：
  描述：

  2-((2-(三氟甲基)苄基)氧基)异吲哚啉e-1,3-二酮 在 氨 、 hydrochloric acid diethyl ether 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 2.0h， 生成 O-[2-(三氟甲基)苄基]羟胺盐酸盐
  参考文献：
  名称：

  多功能小分子作为潜在的抗阿尔茨海默病药物

  摘要：

  阿尔茨海默病（AD）是一种严重的多因素神经退行性疾病，其特征是大脑中神经元的进行性丧失。尽管进行了很多研究，但 AD 进展的发病机制和机制尚未完全清楚。只有少数药物被批准用于治疗 AD。 AD 的多因素特征表明，开发能够针对与该疾病相关的多种病理机制的分子非常重要。因此，在全球公认的多功能配体治疗兴趣的背景下，我们在此报告了一组五种（ 1a - e ）新型阿魏酸杂化化合物（即阿魏酰基-苄氧基酰胺衍生物）的合成、表征、理化和生物学评估包含不同的取代基，作为潜在的抗阿尔茨海默氏病药物。这些杂化物可以保留天然阿魏酸支架的自由基清除活性和金属螯合能力，还表现出良好/温和的抑制自身Aβ聚集的能力以及相当好的抑制Cu诱导的Aβ聚集的能力。与已知的口服药物相比，预测的药代动力学特性表明吸收良好。

  DOI：

  10.3390/molecules26196015
• 作为产物：
  描述：

  N-羟基邻苯二甲酰亚胺 、 2-三氟甲基苯甲醇 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 2-((2-(三氟甲基)苄基)氧基)异吲哚啉e-1,3-二酮
  参考文献：
  名称：

  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1

  摘要：

  Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a. potent sub-micromolar inhibitor of IDO1. Structure activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.028

文献信息

• O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1
  作者：William P. Malachowski、Maria Winters、James B. DuHadaway、Ariel Lewis-Ballester、Shorouk Badir、Jenny Wai、Maisha Rahman、Eesha Sheikh、Judith M. LaLonde、Syun-Ru Yeh、George C. Prendergast、Alexander J. Muller

  DOI：10.1016/j.ejmech.2015.12.028

  日期：2016.1

  Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a. potent sub-micromolar inhibitor of IDO1. Structure activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications. (C) 2015 Elsevier Masson SAS. All rights reserved.
• Multifunctional Small Molecules as Potential Anti-Alzheimer’s Disease Agents
  作者：Beatrice Bargagna、Lidia Ciccone、Susanna Nencetti、M. Amélia Santos、Sílvia Chaves、Caterina Camodeca、Elisabetta Orlandini

  DOI：10.3390/molecules26196015

  日期：——

  with the disease. Thus, in the context of the worldwide recognized interest of multifunctional ligand therapy, we report herein the synthesis, characterization, physicochemical and biological evaluation of a set of five (1a–e) new ferulic acid-based hybrid compounds, namely feroyl-benzyloxyamidic derivatives enclosing different substituent groups, as potential anti-Alzheimer’s disease agents. These hybrids

  阿尔茨海默病（AD）是一种严重的多因素神经退行性疾病，其特征是大脑中神经元的进行性丧失。尽管进行了很多研究，但 AD 进展的发病机制和机制尚未完全清楚。只有少数药物被批准用于治疗 AD。 AD 的多因素特征表明，开发能够针对与该疾病相关的多种病理机制的分子非常重要。因此，在全球公认的多功能配体治疗兴趣的背景下，我们在此报告了一组五种（ 1a - e ）新型阿魏酸杂化化合物（即阿魏酰基-苄氧基酰胺衍生物）的合成、表征、理化和生物学评估包含不同的取代基，作为潜在的抗阿尔茨海默氏病药物。这些杂化物可以保留天然阿魏酸支架的自由基清除活性和金属螯合能力，还表现出良好/温和的抑制自身Aβ聚集的能力以及相当好的抑制Cu诱导的Aβ聚集的能力。与已知的口服药物相比，预测的药代动力学特性表明吸收良好。